NTRK fusion-positive tumors

Roche scores double cancer approval for new Bayer rival Rozlytrek
Fierce Pharma
Thu, 08/15/19 - 11:32 pm
Roche
Rozlytrek
FDA
NTRK fusion-positive tumors
non-small cell lung cancer